Package Leaflet: Information for the User
Telmark 40 mg Film-Coated Tablets EFG
telmisartan
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the package leaflet:
Telmark belongs to a class of medicines known as angiotensin II receptor blockers. Angiotensin II is a substance produced in your body that causes your blood vessels to narrow, thus increasing your blood pressure. Telmark blocks the effect of angiotensin II, causing the blood vessels to relax and your blood pressure to decrease.
Telmark is used to treatessential hypertension (high blood pressure) in adults. "Essential" means that the high blood pressure is not caused by any other condition.
High blood pressure, if left untreated, can damage blood vessels in various organs, which can lead, in some cases, to heart attacks, heart failure, or kidney failure, strokes, or blindness. Usually, there are no symptoms of high blood pressure before damage occurs. Therefore, it is important to regularly measure your blood pressure to check if it is within the normal range.
Telmark is also usedto reduce cardiovascular events (e.g., heart attacks or strokes) in adults at risk because their blood supply to the heart or legs is reduced or blocked, or they have had a stroke or have a high risk of suffering from diabetes. Your doctor will inform you about whether you have a high risk of suffering from these events.
Do not take Telmark
If you think any of the above applies to you, consult your doctor or pharmacist before taking Telmark.
Warnings and precautions
Tell your doctor before starting to take Telmark if you are suffering from or have ever suffered from any of the following conditions or diseases:
Tell your doctor before taking Telmark:
Your doctor should check your kidney function, blood pressure, and the amount of electrolytes (e.g., potassium) in your blood at regular intervals. See also the information in the heading "Do not take Telmark" and "Warnings and precautions".
If you are pregnant (or think you might be), you must inform your doctor. Telmark is not recommended during the first trimester of pregnancy and should not be taken after the third month of pregnancy, as it may cause serious harm to your baby (see section "Pregnancy").
In case of surgery or anesthesia, inform your doctor that you are taking Telmark.
Telmark may be less effective in lowering blood pressure in black patients.
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking Telmark. Your doctor will decide whether to continue treatment. Do not stop taking Telmark on your own.
Children and adolescents
The use of Telmark is not recommended in children and adolescents up to 18 years of age.
Other medicines and Telmark
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Your doctor may need to change the dose of these medicines or take other precautions. In some cases, you may need to stop taking one of the medicines. This is especially true for the following medicines when taken with Telmark:
The effect of Telmark may be reduced when you take non-steroidal anti-inflammatory medicines (e.g., aspirin or ibuprofen) or corticosteroids.
Telmark may increase the blood-pressure-lowering effect of other medicines used to treat high blood pressure or medicines with a potential to lower blood pressure (e.g., baclofen, amifostine). Additionally, low blood pressure may be worsened by alcohol, barbiturates, narcotics, or antidepressants. You may feel dizzy when standing up. Consult with your doctor if you need to adjust the dose of another medicine while taking Telmark.
Pregnancy and breastfeeding
Pregnancy
If you are pregnant (or think you might be), you must inform your doctor. Your doctor will advise you to stop taking Telmark before you become pregnant or as soon as you find out you are pregnant and will recommend taking another blood pressure medicine instead. Telmark should not be used during the first trimester of pregnancy and must not be taken after the third month of pregnancy, as it may cause serious harm to your baby.
Breastfeeding
Tell your doctor if you are about to start or are already breastfeeding. Telmark is not recommended for women who are breastfeeding, and your doctor will choose another treatment for you if you want to start breastfeeding, especially for newborns or premature babies.
Driving and using machines
Some people may experience side effects such as fainting or a feeling of spinning (vertigo) when taking Telmark. If you experience these side effects, do not drive or use machines.
Telmark contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
Telmark contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow exactly the instructions of administration of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.
The recommended dose of Telmark is one tablet per day. Try to take the tablet at the same time every day. You can take Telmark with or without food. The tablets should be swallowed whole with a little water or another non-alcoholic drink. It is important that you take Telmark every day until your doctor tells you to stop. If you think the effect of Telmark is too strong or too weak, talk to your doctor or pharmacist.
For the treatment of high blood pressure, the usual dose of Telmark for most patients is 40 mg once a day, to control blood pressure over 24 hours. However, sometimes your doctor may recommend a lower dose of 20 mg or a higher dose of 80 mg. Alternatively, Telmark can be used in combination with diuretics such as hydrochlorothiazide, which has been shown to have an additive blood-pressure-lowering effect with Telmark.
For the reduction of cardiovascular events, the usual dose of Telmark is one 80 mg tablet once a day. At the start of preventive treatment with Telmark 80 mg, blood pressure should be frequently monitored.
If your liver is not working properly, the usual dose should not exceed 40 mg once a day.
If you take more Telmark than you should
If you have accidentally taken more tablets than you should, inform your doctor or pharmacist immediately or go to the casualty department of your nearest hospital.
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or the Toxicology Information Service (telephone: 91 562 04 20), stating the medicine and the amount taken. It is recommended to take the package and the package leaflet of the medicine to the healthcare professional.
If you forget to take Telmark
If you forget to take a dose, do not worry. Take it as soon as you remember and then continue as before. If you do not take your tablet one day, take your normal dose the next day. Donot take a double dose to make up for forgotten doses.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects can be serious and need immediate medical attention:
Consult your doctor immediately if you experience any of the following symptoms:
Sepsis * (often called "blood poisoning", a serious infection with an inflammatory response throughout the body), rapid swelling of the skin and mucous membranes (angioedema), these side effects are rare (may affect up to 1 in 1,000 patients) but are extremely serious and patients must stop taking this medicine and consult their doctor immediately. If these side effects are not treated immediately, they can be fatal.
Possible side effects of Telmark:
Common side effects (may affect up to 1 in 10 patients):
Low blood pressure (hypotension) in patients treated for cardiovascular event reduction.
Uncommon side effects (may affect up to 1 in 100 patients):
Urinary tract infections, upper respiratory tract infections (e.g., sore throat, sinusitis, common cold), low red blood cell count (anemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in patients treated for high blood pressure, feeling dizzy when standing up (orthostatic hypotension), difficulty breathing, cough, abdominal pain, diarrhea, stomach pain, abdominal distension, vomiting, itching, increased sweating, skin rash, back pain, muscle cramps, muscle pain (myalgia), kidney failure including acute kidney failure, chest pain, feeling weak, and increased creatinine levels in the blood.
Rare side effects (may affect up to 1 in 1,000 patients):
Sepsis * (often called "blood poisoning", a serious infection with an inflammatory response throughout the body that can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g., rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, drowsiness, vision problems, rapid heart rate (tachycardia), dry mouth, abdominal discomfort, taste disturbances (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect), rapid swelling of the skin and mucous membranes that can lead to death (angioedema including fatal outcome), eczema (a skin disease), skin redness, hives (urticaria), severe skin rash caused by medicines, joint pain (arthralgia), pain in the limbs, tendon pain, pseudogripal illness, decrease in hemoglobin (a blood protein), increase in uric acid levels, increase in liver enzymes or creatine phosphokinase in the blood, low sodium levels.
Very rare side effects (may affect up to 1 in 10,000 patients):
Progressive scarring of lung tissue (interstitial lung disease).**
Frequency not known (cannot be estimated from the available data):
Intestinal angioedema: swelling in the intestine has been reported, with symptoms such as abdominal pain, nausea, vomiting, and diarrhea after taking similar products.
** Cases of progressive scarring of lung tissue have been detected during the intake of telmisartan. However, it is not known whether telmisartan was the cause of this.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines Agency's Pharmacovigilance System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after "EXP". The expiry date refers to the last day of the month stated.
This medicine does not require any special storage conditions. Store in the original package to protect from moisture. Remove the Telmark tablets from the blister pack immediately before consumption.
Medicines should not be disposed of via wastewater or household waste. Return the package and any unused medicine to a pharmacy for proper disposal. Ask your pharmacist how to dispose of the package and any unused medicine. This will help protect the environment.
Composition of Telmark
The active substance is telmisartan. Each tablet contains 40 mg of telmisartan.
The other ingredients are:
Core:
Sodium hydroxide
Povidone (K-25)
Meglumine
Lactose monohydrate
Crospovidone
Yellow iron oxide (E172)
Magnesium stearate
Coating:
Hypromellose
Titanium dioxide (E171)
Macrogol-400
Talc
Yellow iron oxide (E172)
Appearance of the product and pack contents
Telmark are film-coated tablets, capsule-shaped, yellow, with a '40' engraved on one face and a 'T' engraved on the other face.
Telmark is available in blister packs containing 14, 15, 28, 30, 56, 60, 90, or 98 tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Marketing authorisation holder:
Glenmark Pharmaceuticals s.r.o.
Hvezdova 1716/2b
140 78 Praha 4
Czech Republic
Manufacturer:
Glenmark Pharmaceuticals s.r.o.
Fibichova, 143
56617 Vysoke Myto
Czech Republic
You can ask for more information about this medicine from the representative of the marketing authorisation holder:
Glenmark Farmacéutica, S.L.U.
C/ Retama 7, 7th floor
28045 Madrid
Spain
This medicine is authorised in the Member States of the European Economic Area under the following names:
Sweden: Telmark 40 mg film-coated tablets
Slovakia: Telmark 40 mg film-coated tablets
Spain: Telmark 40 mg film-coated tablets EFG
Finland: TELMARK 40 mg tablet, film-coated
Date of last revision of this leaflet:March 2025.
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)
The average price of TELMARK 40 mg FILM-COATED TABLETS in October, 2025 is around 9.99 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.